Gout, a disease recognized since antiquity, has increased in prevalence in recent years and the clinical profile of this disease has become increasingly complex, owing to large numbers of cases with iatrogenic factors, multiple comorbidities, advanced age, and hyperuricemia and arthritis refractory to treatment. In this Review, key advances in gout research made during the past decade are summarized. Revised strategies for safe and effective employment of dietary measures and pharmacologic treatments for active gouty arthritis, prevention of gout flares and urate lowering are also reviewed, with an emphasis on dosing of colchicine and allopurinol, and the evidence-based approach to systemic glucocorticosteroid treatment of acute gout. Also discussed are new and emerging treatments for gout and hyperuricemia, and the potential influence of dual energy CT imaging on treatment. In this context, the therapeutic role of febuxostat, and clinical development of pegylated uricase urate-lowering therapy and interleukin 1 antagonism for gouty inflammation are reviewed. Collectively, novel approaches will hopefully lead to improved management of hyperuricemia and gout, and also to improvements in patient-centered outcomes, even for those who have previously failed to respond to treatment.
The prevalence of gout has approximately doubled in the past two decades, along with increases in its severity, treatment complexity and refractoriness
Major advances have been made in understanding the link between inherited susceptibility to gout and altered renal urate disposition
These advances have the potential to improve risk stratification for patients with incident gout and to optimize urate-lowering therapy via pharmacogenomics
Evolution in the evidence base for allopurinol, colchicine and oral glucocorticosteroid administration has validated improved and cost-effective treatment strategies for most patients
Febuxostat and biologic agents in development (interleukin 1 inhibitors and pegloticase) represent substantial therapeutic advances, particularly for severe, treatment-refractory gout, and patients with comorbidities or intolerance to other drugs
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Mandell, B. F. Clinical manifestations of hyperuricemia and gout. Cleve. Clin. J. Med. 75 (Suppl. 5), S5–S8 (2008).
Liebman, S. E., Taylor, J. G. & Bushinsky, D. A. Uric acid nephrolithiasis. Curr. Rheumatol. Rep. 9, 251–257 (2007).
Wortmann, R. L. Gout and hyperuricemia. Curr. Opin. Rheumatol. 14, 281–286 (2002).
Dalbeth, N. & Haskard, D. O. Mechanisms of inflammation in gout. Rheumatology (Oxford) 44, 1090–1096 (2005).
Choi, H. K. et al. Dual energy computed tomography in tophaceous gout. Ann. Rheum. Dis. 68, 1609–1612 (2009).
Feig, D. I., Kang, D. H. & Johnson, R. J. Uric acid and cardiovascular risk. N. Engl. J. Med. 359, 1811–1821 (2008).
Bieber, J. D. & Terkeltaub, R. A. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum. 50, 2400–2414 (2004).
Zharikov, S. et al. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am. J. Physiol. Cell Physiol. 295, C1183–C1190 (2008).
Hak, A. E. & Choi, H. K. Lifestyle and gout. Curr. Opin. Rheumatol. 20, 179–186 (2008).
Wallace, K. L., Riedel, A. A., Joseph-Ridge, N. & Wortmann, R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J. Rheumatol. 31, 1582–1587 (2004).
Lawrence, R. C. et al. National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 58, 26–35 (2008).
Sundy, J. S. & Hershfield, M. S. Uricase and other novel agents for the management of patients with treatment-failure gout. Curr. Rheumatol. Rep. 9, 258–264 (2007).
Endou, H. & Anzai, N. Urate transport across the apical membrane of renal proximal tubules. Nucleosides Nucleotides Nucleic Acids 27, 578–584 (2008).
Anzai, N. et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J. Biol. Chem. 283, 26834–26838 (2008).
Dehghan, A. et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 372, 1953–1961 (2008).
Woodward, O. M. et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc. Natl Acad. Sci. USA 106, 10338–10342 (2009).
Urano, W. et al. Sodium-dependent phosphate cotransporter type 1 (NPT1) sequence polymorphisms in male patients with gout. Ann. Rheum. Dis. doi:10.1136/ard.2008.106856.
Matsuo, H. et al. Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am. J. Hum. Genet. 83, 744–751 (2008).
Brandstätter, A. et al. Sex-specific association of the putative fructose transporter SLC2A9 variants with uric acid levels is modified by BMI. Diabetes Care 31, 1662–1667 (2008).
Cronstein, B. N. & Terkeltaub, R. The inflammatory process of gout and its treatment. Arthritis Res. Ther. 8 (Suppl. 1), S3 (2006).
Liu-Bryan, R., Scott, P., Sydlaske, A., Rose, D. M. & Terkeltaub, R. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum. 52, 2936–2946 (2005).
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237–241 (2006).
Hornung, V. et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9, 847–856 (2008).
Terkeltaub, R. A. Clinical practice. Gout. N. Engl. J. Med. 349, 1647–1655 (2003).
Zhang, W. et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 65, 1312–1324 (2006).
Briesacher, B. A., Andrade, S. E., Fouayzi, H. & Chan, K. A. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 28, 437–443 (2008).
Harrold, L. R. et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res. Ther. 11, R46 (2009).
Terkeltaub, R. A. Colchicine Update: 2008. Semin. Arthritis Rheum. 38, 411–419 (2008).
Man, C. Y., Cheung, I. T., Cameron, P. A. & Rainer, T. H. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute gout like arthritis: a double-blind, randomized, controlled trial. Ann. Emerg. Med. 49, 670–677 (2007).
Janssens, H. J., Janssen, M., van de Lisdonk, E. H., van Riel, P. L. & van Weel, C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 371, 1854–1860 (2008).
Rubin, B. R. et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum. 50, 598–606 (2004).
Getting, S. J., Lam, C. W., Chen, A. S., Grieco, P. & Perretti, M. Melanocortin 3 receptors control crystal-induced inflammation. FASEB J. 20, 2234–2241 (2006).
Terkeltaub, R., Furst, D., Bennett, K., Kook, K. & Davis, M. Low dose (1.8 mg) vs high dose (4.8 mg) oral colchicine regimens in patients with acute gout flare in a large, multicenter, randomized, double-blind, placebo-controlled, parallel group study [abstract 1944]. Arthritis Rheum. 58 (Suppl.), S879 (2008).
So, A., De Smedt, T., Revaz, S. & Tschopp, J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9, R28 (2007).
Terkeltaub, R. et al. The IL-1 inhibitor rilonacept in treatment of chronic gouty arthritis: Results of a placebo-controlled, monosequence crossover, nonrandomized, single-blind pilot study. Ann. Rheum. Dis. 68, 1613–1617 (2009).
Schumacher, R. H. et al. Placebo-controlled study of rilonacept for prevention of gout flares during initiation of urate-lowering therapy. Ann. Rheum. Dis. 68 (Suppl. 3), 680 (2009).
Chao, J. & Terkeltaub, R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr. Rheumatol. Rep. 11, 135–140 (2009).
Perez-Ruiz, F. & Lioté, F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum. 57, 1324–1328 (2007).
Edwards, N. L. Treatment-failure gout: a moving target. Arthritis Rheum. 58, 2587–2590 (2008).
Becker, M. A. et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med. 353, 2450–2461 (2005).
Schumacher, H. R. Jr, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 59, 1540–1548 (2008).
Becker, M. et al. A phase 3 randomized, controlled, multicenter, double-blind trial (RCT) comparing efficacy and safety of daily febuxostat (FEB) and allopurinol (ALLO) in subjects with gout [abstract L11]. Arthritis Rheum. 58 (Suppl.), (2008).
Perez-Ruiz, F. et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann. Rheum. Dis. 57, 545–549 (1998).
Reinders, M. K. et al. A randomized controlled trial on the efficacy and tolerability with dose-escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Ann. Rheum. Dis. 68, 892–897 (2009).
Sarawate, C. A. et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin. Proc. 81, 925–934 (2006).
Dalbeth, N. & Stamp, L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin. Dial. 20, 391–395 (2007).
Perez-Ruiz, F., Hernando, I., Villar, I. & Nolla, J. M. Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol-related toxicity. J. Clin. Rheumatol. 11, 129–133 (2005).
Schumacher, H. R., Jr, Becker, M. A., Lloyd, E., MacDonald, P. A. & Lademacher, C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 48, 188–194 (2009).
Perez-Ruiz, F., Calabozo, M., Pijoan, J. I., Herrero-Beites, A. M. & Ruibal, A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 7, 56–60 (2002).
Reinders, M. K., van Roon, E. N., Houtman, P. M., Brouwers, J. R. & Jansen, T. L. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin. Rheumatol. 26, 1459–1465 (2007).
Terkeltaub, R. Learning how and when to employ uricase as bridge therapy in refractory gout. J. Rheumatol. 34, 1955–1958 (2007).
Sundy, J. S. et al. Efficacy and safety of intravenous (IV) pegloticase (PGL) in subjects with treatment failure gout (TFG): Phase 3 results from GOUT1 and GOUT2 [Abstract]. Arthritis Rheum. 58 (Suppl.), S400 (2008).
Baraf, H. S. et al. Tophus response to pegloticase (PGL) therapy: pooled results from GOUT1 and GOUT2, PGL phase 3 randomized, double blind, placebo-controlled trials [Abstract]. Arthritis Rheum. 58 (Suppl.), S176 (2008).
Becker, M. A. et al. Quality of life and disability in patients with treatment-failure gout. J. Rheumatol. 36, 1041–1048 (2009).
Becker, M. A. et al. Immunoreactivity and clinical response to pegloticase (PGL): pooled data from GOUT1 and GOUT2 PGL phase 3 randomized, double blind, placebo-controlled trials [abstract 1945]. Arthritis Rheum. 58 (Suppl.), S880 (2008).
Sundy, J. S. et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 58, 2882–2891 (2008).
Terkeltaub, R. Gout. Novel therapies for treatment of gout and hyperuricemia. Arthritis Res. Ther. 11, 236 (2009).
Borstad, G. C. et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J. Rheumatol. 31, 2429–2432 (2004).
Singh, J. A. Quality of life and quality of care for patients with gout. Curr. Rheumatol. Rep. 11, 154–160 (2009).
Mikuls, T. R. Quality of care in gout: from measurement to improvement. Clin. Exp. Rheumatol. 25 (Suppl. 47), 114–119 (2007).
Neogi, T., Hunter, D. J., Chaisson, C. E., Allensworth-Davies, D. & Zhang, Y. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J. Rheumatol. 33, 104–109 (2006).
Singh, J. A. & Strand, V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann. Rheum. Dis. 67, 1310–1316 (2008).
Krishnan, E., Svendsen, K., Neaton, J. D., Grandits, G. & Kuller, L. H. MRFIT Research Group: long-term cardiovascular mortality among middle-aged men with gout. Arch. Intern. Med. 168, 1104–1110 (2008).
Wall, G. C., Koenigsfeld, C. F., Hegge, K. A. & Bottenberg, M. M. Adherence to treatment guidelines in two primary care populations with gout. Rheumatol. Int. doi:10.1007/s00296-009-1056-7.
Wu, E. Q. et al. Disease-related and all-cause health care costs of elderly patients with gout. J. Manag. Care Pharm. 14, 64–175 (2008).
Dr. Terkeltaub is supported by the Research Service of the US Department of Veterans Affairs. Charles P. Vega, University of California, Irvine, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the MedscapeCME-accredited continuing medical education activity associated with this article.
Dr. Terkeltaub has served as consultant for Altus, Ardea Biosciences, BioCryst Pharmaceuticals, EnzymeRx, Novartis, Pfizer, Regeneron, Savient Pharmaceuticals, Takeda and URL Pharma. Dr. Terkeltaub also is the past recipient of research grant support from Takeda.
About this article
Cite this article
Terkeltaub, R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 6, 30–38 (2010). https://doi.org/10.1038/nrrheum.2009.236
Inflammation Research (2022)
Effects of Gentiopicroside on activation of NLRP3 inflammasome in acute gouty arthritis mice induced by MSU
Journal of Natural Medicines (2022)
Impact of Lesinurad and allopurinol on experimental Hyperuricemia in mice: biochemical, molecular and Immunohistochemical study
BMC Pharmacology and Toxicology (2020)
Molecular and Histopathological Study on the Ameliorative Impacts of Petroselinum Crispum and Apium Graveolens against Experimental Hyperuricemia
Scientific Reports (2020)
Nature Biotechnology (2020)